SCHEMBL9979780

SCHEMBL9979780

Oc1cc2nc3cc(O)c(O)cc3nc2cc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
KDM4E B2RXH2 3/20 0.46
RPS6KB2 Q9UBS0 1/20 0.44
MYC P01106 1/20 0.41
MAX P61244 1/20 0.41
NQO2 P16083 3/20 0.39
NQO1 P15559 1/20 0.37
EGFR P00533 2/20 0.37
PDGFRB P09619 2/20 0.37
PDGFRA P16234 2/20 0.37
SNCA P37840 1/20 0.37
PGK1 P00558 1/20 0.37
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP2C19 P33261 1/20 0.36
APP P05067 1/20 0.35
ACHE P22303 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16547258 0.86 KDM4E (0.42) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL11995959 0.86 ACHE (0.43) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL2449714 0.85 KDM4E (0.68) MAPTKDM4ERPS6KB2NQO2PDGFRB
SCHEMBL29489945 0.85 NQO2 (0.62) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL2368230 0.85 NQO2 (0.57) MAPTKDM4ERPS6KB2NQO2PGK1
SCHEMBL2367850 0.85 NQO2 (0.62) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL9979779 0.83 EGFR (0.42) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL15581107 0.83 KDM4E (0.58) MAPTKDM4ERPS6KB2NQO2ALDH1A1
SCHEMBL9979793 0.81 NQO1 (0.36) MAPTKDM4ERPS6KB2MYCMAX
SCHEMBL3722904 0.81 KDM4E (0.48) KDM4ERPS6KB2MYCMAXKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10454124-B2 Highly stable phenazine derivatives for aqueous redox flow batteries BATTELLE MEMORIAL INSTITUTE (US) 2019-10-22 US disclosed
US-9978474-B2 Conductive open frameworks THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-05-22 US disclosed
US-20160247593-A1 CONDUCTIVE OPEN FRAMEWORKS UNITED STATES DEPARTMENT OF ENERGY 2016-08-25 US disclosed
US-9269473-B2 Conductive open frameworks THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-02-23 US disclosed
WO-2012082213-A2 CONDUCTIVE OPEN FRAMEWORKS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160247593-A1 CONDUCTIVE OPEN FRAMEWORKS GJB2, OR10J3, EPCAM MAPT 3871/4885KDM4E 2184/4885RPS6KB2 3039/4885
US-10454124-B2 Highly stable phenazine derivatives for aqueous redox flow batteries NDUFS5, NDUFS2, NDUFV1 MAPT 1172/4885KDM4E 3006/4885RPS6KB2 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.